Overview A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma Status: Not yet recruiting Trial end date: 2023-09-01 Target enrollment: Participant gender: Summary This study will assess the efficacy and safety of 610 as an adjunctive therapy in adult subjects with severe eosinophilic asthma. Phase: Phase 2 Details Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.